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PCLINICAL RESEARCH Clinical Trial
The Reno-Protective Effect of Hydration With
Sodium Bicarbonate Plus N-Acetylcysteine in Patients
Undergoing Emergency Percutaneous Coronary Intervention
The RENO Study
Alejandro Recio-Mayoral, MD,* Marinela Chaparro, MD,* Belén Prado, MD,* Rocío Cózar, MD,*
Irene Méndez, MD,* Debasish Banerjee, MD, MRCP,† Juan C. Kaski, MD, DM, DSC,‡
José Cubero, MD,* Jose M. Cruz, MD*
Seville, Spain; and London, United Kingdom
Objectives This study was designed to determine the effectiveness of a protocol for rapid intravenous hydration to prevent
contrast-induced nephropathy (CIN) in patients undergoing emergency percutaneous coronary intervention (PCI).
Background Contrast-induced nephropathy frequently complicates PCI, resulting in prolonged hospitalization and increased
in-hospital and long-term morbidity and mortality. Little is known regarding prevention of CIN in patients under-
going urgent PCI.
Methods We conducted a prospective, controlled, randomized, single-center trial in 111 consecutive patients with acute
coronary syndrome undergoing emergency PCI. As part of the hydration therapy, 56 patients (group A) received
an infusion of sodium bicarbonate plus N-acetylcysteine (N-AC) started just before contrast injection and contin-
ued for 12 h after PCI. The remaining 55 patients (group B) received the standard hydration protocol consisting
of intravenous isotonic saline for 12 h after PCI. In both groups, 2 doses of oral N-AC were administered the next day.
Results The 2 groups were similar with respect to age, gender, diabetes mellitus, and baseline serum creatinine. A se-
rum creatinine concentration 0.5 mg/dl from baseline after emergency PCI was observed in 1 patient in group
A (1.8%) and in 12 patients in group B (21.8%; p  0.001). Acute anuric renal failure was observed in 1 patient
(1.8%) in group A and in 7 patients (12.7%) in group B (p  0.032).
Conclusions Rapid intravenous hydration with sodium bicarbonate plus N-AC before contrast injection is effective and safe in
the prevention of CIN in patients undergoing emergency PCI. (J Am Coll Cardiol 2007;49:1283–8) © 2007 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.11.034s
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Iodinated contrast media are being used increas-
ingly in the catheterization laboratory during
diagnostic catheterization and percutaneous cor-
onary intervention (PCI). Contrast-induced ne-
phropathy (CIN) is a major cause of morbidity
and mortality associated with PCI (1). The over-
ll incidence of CIN after PCI has been reported between 3.3%
nd 16.5% (1,2), although this figure increases up to 50% in
igh-risk patients (3). In Europe, CIN is the third highest
ause of acute renal failure, accounting for 10% of all causes of
ospital-acquired renal failure (4). Several therapies for pre-
enting CIN have been tested in patients undergoing elective
CI, with differing results. Only intravenous hydration with
rom the *Department of Cardiology, Virgen Macarena University Hospital, Seville,
pain; and the †Department of Renal and Transplantation and ‡Division of Cardiac
nd Vascular Sciences, St. George’s Hospital, University of London, London, United
ingdom.a
Manuscript received August 16, 2006; revised manuscript received November 1,
006, accepted November 16, 2006.aline has been shown repeatedly to provide effective and safe
rophylaxis for CIN in these patients (5). In the pathogenesis
f CIN, renal ischemia and free radical formation induced by
he contrast medium play an important role (6). Based on the
ypothesis that alkalizing the renal tubule should confer
rotection against CIN in a prospective trial, Merten et al. (7)
ompared hydration with intravenous sodium bicarbonate and
odium chloride starting 1 h before contrast exposition. They
howed that intravenous hydration with sodium bicarbonate
rovides greater benefits in the prevention of CIN (1.7% vs.
3.6%, p  0.02). The results from the study by Merten et al.
7) with bicarbonate have not been replicated by others.
-acetylcysteine (N-AC), a potent antioxidant either directly
s a free radical scavenger or indirectly through glutation
roduction (8,9), may play an additional role in the prevention
f CIN. Although several studies on the prophylactic effect of
-AC have given conflicting results, recent studies support a
ose-dependent effect (10–12), suggesting that a higher dose
ould be needed in high-risk patients, in whom greater
mounts of contrast could be administered.
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Contrast Nephropathy Prevention in Emergency PCI March 27, 2007:1283–8Patients undergoing emer-
gency PCI represent a high-risk
population for CIN, as opposed
to those undergoing elective PCI
(13). Various conditions may
contribute to renal injury in this
setting (i.e., hypotension and ex-
posure to large volumes of con-
trast media), along with difficul-
ties in establishing a prophylactic
therapy in the acute setting.
A rapid hydration with saline
sodium bicarbonate, in addition
to causing intravascular volume
expansion, could provide addi-
tional effects over the free radical
scavenger properties of N-AC.
o assess the effectiveness and safety of a CIN prevention
rotocol with sodium bicarbonate hydration plus N-AC, we
arried out the RENO (Reno-Protective Effect of Hydra-
ion With Sodium Bicarbonate Plus N-Acetylcysteine in
atients Undergoing Emergency Percutaneous Coronary
ntervention) study, a randomized, single-blind, single-
enter trial in patients undergoing emergency PCI.
ethods
atients. We prospectively studied 111 consecutive acute
oronary syndrome (ACS) patients who were admitted to
ur coronary care unit between December 2004 and May
005. All patients with myocardial infarction treated with
rimary PCI or rescue PCI, as well as patients with high-risk
on–ST-segment elevation ACS needing urgent revasculariza-
ion, were included. Urgent PCI was considered in high-risk
on–ST-segment elevation ACS, defined by the following
riteria: recurrent resting chest pain not responding to
reatment, hemodynamic instability and cardiogenic shock,
ajor arrhythmias, and early postinfarction unstable angina
14). In all cases, the coronary angiography was performed
ithin the first 12 h from the onset of symptoms.
Cardiogenic shock was defined as prolonged hypotension
systolic blood pressure 90 mm Hg for at least 30 min)
aused by severe left ventricular dysfunction or right ven-
ricular infarction, requiring inotropic support medication
nd/or intra-aortic balloon pump to maintain a systolic
lood pressure of 90 mm Hg (15).
There were no inclusion criteria based on glomerular filtra-
ion rate (GFR). Patients with end-stage renal failure on
ialysis, uncontrolled hypertension (systolic blood pressure
160 mm Hg and/or diastolic blood pressure 100 mm Hg)
nd signs of cardiac failure not responding to medical treat-
ent, known severe aortic valve stenosis (area 1.0 cm2),
llergy to iodated contrast or N-AC, and pregnancy were
xcluded from the study. The study protocol was reviewed
nd approved by the local ethics committee, and all patients
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
BUN  blood urea nitrogen
CI  confidence interval
CIN  contrast-induced
nephropathy
GFR  glomerular filtration
rate
N-AC  N-acetylcysteine
OR  odds ratio
PCI  percutaneous
coronary intervention
SCr  serum creatinineave written informed consent before the study entry. rtudy protocol. Patients were randomly assigned to an
ctive prophylactic treatment before PCI (group A) or to
tandard hydration after the procedure (group B). The
atients allocated to group A received an initial intravenous
olus of 5 ml/kg/h of alkaline saline solution with 154
Eq/l of sodium bicarbonate in 5% glucose and H2O
adding 77 ml of 1,000 mEq/l sodium bicarbonate to 433 ml
f 5% glucose in H2O) plus 2,400 mg of N-AC in the same
olution over 1 h. In all patients, the bolus was administered
n the 60 min preceding contrast injection. Afterward,
atients received fluid therapy, without N-AC, at 1.5
l/kg/h perfusion rate in the 12 h after the procedure plus
doses of 600 mg N-AC orally the next day. Patients in
roup B were treated according to our institution protocol
ith perfusion of isotonic saline (0.9%) at rate of 1 ml/kg/h
or 12 h after PCI plus 2 doses of 600 mg N-AC orally the
ext day. In both groups, the maximum dose administered
as that administered for patients weighing 100 kg.
There was no limitation in concomitant treatment, in-
luding diuretics and angiotensin-converting enzyme inhib-
tors, which were left to the discretion of the interventional
nd coronary care unit cardiologists. Only the patients were
linded and not told to which group they were randomized.
Coronary angiography was performed according to stan-
ard clinical practice using the femoral approach. The
ow-osmolality nonionic contrast medium Iomeprol
Iomeron, Bracco s.p.a, Milan, Italy) with 350 mg/ml of
odine content was used in all cases. All decisions regarding
rocedural hemodynamics, including contrast doses, were
eft to the discretion of the interventional cardiologist.
Serum creatinine (SCr) and blood urea nitrogen (BUN)
oncentrations were measured at admission, daily for the
ext 3 days, and on day 7 after the procedure. The GFR was
alculated using the Modification of Diet in Renal Disease
tudy group equation (16). Likewise, arterial blood pH was
ssessed immediately before the procedure and 2 h thereaf-
er. Diuresis was collected for 24 h after the procedure.
The primary end point was the development of acute
IN, defined as an absolute increase in SCr concentration
f 0.5 mg/dl or more from baseline value in the 3 days after
CI (17–19). The following secondary end points were
ssessed: 1) other conventional definitions of CIN: an
ncrease in SCr 25% over the baseline value and 50%
ver the baseline value, both within the first 3 days (6,19);
nd 2) adverse clinical events, including acute pulmonary
dema during and after the procedure, acute anuric renal
ailure that did or did not result in temporary renal replace-
ent therapy, and death in the 7 days after the procedure.
enal replacement therapy (hemodialysis or hemofiltra-
ion) was undertaken in patients with anuria (urine
utput 20 ml/h) despite the administration of more than
g intravenous furosemide and presence of volume overload
nd/or BUN 200 mg/dl.
tatistical analysis. We calculated the sample size of our
tudy assuming a CIN rate of 20% in group B based on the
ate previously reported by Marenzy et al. (13) in patients
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March 27, 2007:1283–8 Contrast Nephropathy Prevention in Emergency PCIndergoing primary PCI. For group A, patients treated with
odium bicarbonate and a high dose of N-AC, we assumed
CIN rate of 3%, similar to that reported by Briguori et al.
11) using high doses of N-AC (3.5%) and by Merten et al.
7) using sodium bicarbonate (1.7%). Analysis indicated
hat a sample size of 55 patients would be necessary in each
rm to detect a statistically significant different with a power
f 80%, with a type I error of 0.05.
Analysis was conducted on an intention-to-treat basis.
ategorical variables were expressed as percentages and
nalyzed by chi-square or Fisher exact test as appropriate.
ontinuous variables were expressed as mean  SD and
ompared with the t test, except levels of SCr and BUN,
hich were compared with the nonparametric Wilcoxon-
ann-Whitney U test. We used Spearman correlation
oefficients to evaluate the relationship between volumes of
ontrast medium administered during procedure and max-
mum change in SCr from the baseline value in the first 3
ays after PCI. A repeated-measures analysis of variance
as used to test the interaction of treatment in the evolution
f GFR during follow-up. Multivariate logistic regression
nalysis was performed to examine the effects of different
ossible confounding variables on the incidence of CIN. All
tatistical analyses were performed with the Statistical Pack-
ge for the Social Sciences version 13.0 (SPSS Inc., Chi-
ago, Illinois). A 2-sided p value of0.05 was considered to
e significant.
esults
aseline characteristics. Of the 120 patients randomized,
11 (34 women, ages 65 10 years) had SCr measurements
ompleted and were included in the study. The baseline
haracteristics of the patients are shown in Table 1.
reatment compliance. In group A, the therapy was
iscontinued prematurely in 2 patients; in 1 diabetic patient
ith severe left ventricular dysfunction, the protocol was
topped after bolus perfusion as a result of a pulmonary
dema clinic just after a left ventriculography was per-
ormed. This patient required intravenous nitrates and
urosemide and CIN developed afterward, with a maximum
Cr of 1.7 mg/dl. The other case was a high-risk non–ST-
egment elevation ACS patient with PCI on the right
oronary artery, in whom perfusion was stopped 4 h after
CI subsequent to the development of a right ventricular
nfarction. Bolus administration of sodium saline was given
efore a new procedure was carried out because of an acute
n-stent thrombosis that was treated with a new bare-metal
tent; CIN did not develop in this patient.
ntervention data and analyses. There were no signifi-
ant differences in SCr and BUN values measured im-
ediately before the procedure (baseline) (Table 2).
rterial blood pH before the catheterization was similar in
oth groups (7.37  0.04 in group A vs. 7.37  0.04 in
roup B, p  0.84). Two hours after contrast administra-
ion, patients in group A showed a serum alkalinization, thereas patients in group B experienced a decrease in serum
H (7.41  0.03 vs. 7.36  0.03 respectively, p  0.0001)
Table 2).
The diuresis measured in the 24 h after contrast infusion
as significantly lower in group B than group A (1,955 
29 ml/24 h vs. 3,098  693 ml/24 h, p  0.0001). The
ean contrast volume administered was not significantly
ifferent in group A versus group B (Table 2). However,
hen the response of individuals patients was assessed in
ach group, we found that in group B patients there was a
igher change in SCr in patients who received a large
olume of contrast medium (r  0.45; p  0.0006) (Fig. 1).
n group A patients, however, no relationship was found
etween contrast volume administered and change in SCr
evels (r  0.034; p  0.80).
IN incidence and clinical outcomes. In a total of 13
atients CIN developed: 12 in group B (21.8%) and 1
1.8%) in group A (difference 20%, 95% confidence interval
CI] 8% to 31%, p  0.0009) with an odds ratio (OR) of
.065 (95% CI 0.008 to 0.521, p  0.01) for patients in
roup A. The absolute risk reduction of CIN in group A
ompared with group B was 20%, resulting in a number
equired to treat of 5 patients to prevent 1 case of CIN. In
aseline Characteristic of the Study Patients
Table 1 Baseline Characteristic of the Study Patients
Group A
n  56
Group B
n  55
p
Value
Age 65 10 64 9 0.92
Age 70 yrs 17 (30%) 18 (33%) 0.84
Gender, male 38 (68%) 39 (71%) 0.84
Hypertension 33 (60%) 32 (58%) 0.94
Diabetes mellitus 18 (32%) 15 (27%) 0.58
Dyslipidemia 32 (57%) 29 (52%) 0.64
Baseline serum creatinine (mg/dl)* 1.0 (0.8–1.1) 1.0 (0.9–1.2) 0.31†
Baseline glomerular filtration
rate (ml/min)
75 21 74 20 0.82
History of congestive heart failure 6 (11%) 10 (18%) 0.26
History of myocardial infarction 14 (25%) 9 (16%) 0.26
Peripheral vascular disease 4 (7%) 5 (9%) 0.74
Previous treatment with ACE
inhibitors
27 (48%) 23 (47%) 0.89
LVEF (%) 50 11 51 11 0.71
LVEF 40% 11 (20%) 8 (15%) 0.62
Previous chronic renal insufficiency 4 (7%) 5 (9%) 0.74
Glomerular filtration rate 60
(ml/min)
16 (29%) 14 (25%) 0.83
Anterior ischemia 27 (48%) 20 (36%) 0.21
STEMI 32 (57%) 34 (62%) 0.61
NSTEMI 24 (43%) 21 (38%) 0.61
Primary PCI 23 (41%) 25 (46%) 0.64
Rescue PCI 9 (16%) 9 (16%) 0.97
Cardiogenic shock 5 (9%) 4 (7%) 0.75
lus-minus values are mean SD by Fisher exact test. Group A: sodium bicarbonate infusion plus
igh-dose N-acetylcysteine started just before procedure. Group B: standard hydration protocol.
Median and interquartile ranges. †By nonparametric Wilcoxon rank test.
ACE  angiotensin-converting enzyme; LVEF  left ventricular ejection fraction; NSTEMI 
on–ST-segment elevation acute myocardial infarction; PCI percutaneous coronary intervention;
TEMI  ST-segment elevation acute myocardial infarction.he multivariate analysis adjusted for age, baseline SCr, left
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Contrast Nephropathy Prevention in Emergency PCI March 27, 2007:1283–8entricular function, and volume of contrast medium, the
R in patients allocated to group A was 0.002 (95% CI
.0004 to 0.102, p  0.002). The incidences of CIN using
ifferent criteria are shown in Figure 2.
The difference found in CIN rates between groups was
ot related to depressed left ventricular function nor on
aseline reduced renal function. No significant interactions
ere found between protocol and left ventricular function
p  0.17) or GFR (p  0.29).
The GFR measured at baseline was comparable in the 2
roups (74  20 ml/min in the control group vs. 75  21
l/min in the treatment group, p  0.82). As shown in
igure 3, in group B there was a significant deterioration of
FR that reached a trough at day 3 after the procedure, and
here was a significant improvement in GFR in group A,
vident from the first day (p  0.009 for the trend).
There was a significant difference between groups in the
ate of acute anuric renal failure, 7 patients (12.7%) and 1
atient (1.8 %) in groups B and A, respectively (p  0.032,
5% CI 0.2 to 0.13). Four patients required renal replace-
ent therapy, 3 in group B and 1 in group A. Acute renal
Basal Renal Function, Contrast Volume, andSerum pH in Control Group and Treatment Group
Table 2 Basal Renal Function, Contrast VolSerum pH in Control Group and Trea
Baseline serum creatinine (mg/dl)* 1.0
Baseline blood urea nitrogen (mg/dl)* 17.76
Baseline glomerular filtration rate (ml/min)
Contrast volume (ml) 2
Precontrast serum pH 7.
Postcontrast serum pH 7.
To convert serum creatinine to mol/l, multiply by 88.4. Plus-minus va
†By nonparametric Wilcoxon rank test.
Figure 1 Volumes of Contrast Medium (ml) Correlated With
Maximum Change in SCr 72 h After PCI
The solid lines represent the point estimated, and the upper and
lower lines represent 2 SD. PCI  percutaneous coronary intervention; SCr 
serum creatinine.ailure developed in this latter patient more than 72 h after
dmission, and therefore did not meet criteria for CIN
Table 3).
Acute heart failure during the catheterization developed
n 2 patients in group B and 1 in group A (3.6% vs. 1.8%,
 0.62). The CIN developed during the monitoring in
hese 3 patients.
In our study, the global mortality was 4.5%, but we did
ot find a significant difference in global mortality during
he 7 days of monitoring between groups, 1 patient in group
(died of cardiogenic shock) and 4 patients in group B
2 patients died of cardiogenic shock and 2 patients died of
ultiorgan failure) (Table 3).
iscussion
he results of our study suggest that in patients undergoing
mergency PCI, rapid hydration with saline sodium bicar-
onate and high doses of N-AC just before contrast
njection reduce renal dysfunction and the rate of CIN as a
esult of reduced oxidative stress.
The overall incidence of acute pulmonary edema (2.7%)
as similar to that reported in previous studies (7,10,13). It
Figure 2 Incidence of Contrast-Induced
Nephropathy Based on the Criteria Used
Cr  creatinine.
and
t Group
A Group B p Value
.1) 1.0 (0.9–1.2) 0.31†
–22.20) 17.76 (16.01–21.03) 0.31†
1 74 20 0.82
14 279 94 0.59
.04 7.37 0.04 0.84
.03 7.36 0.03 0.0001
e mean  SD by Fisher exact test. *Median and interquartile ranges.ume,
tmen
Group
(0.8–1
(14.02
75 2
90 1
37 0
41 0
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March 27, 2007:1283–8 Contrast Nephropathy Prevention in Emergency PCIs worth noting that the incidence of acute pulmonary
dema did not differ between groups.
We used SCr for assessment of renal function. However,
t is conceivable that cystatin C levels, a marker of GFR that
s not affected by tubular transport, could have been a better
ndicator of kidney function (20).
Several studies have shown that CIN after an inter-
entional procedure is a frequent complication associated
ith poor outcome (1,2,21). A standardized saline hy-
ration strategy has been shown to be effective in
ecreasing the risk of CIN (17,22). Most studies have
valuated intravenous hydration regimens with saline at a
ate of 1 ml/kg/h, 6 to 12 h before and after contrast
xposure in patients undergoing elective procedures
11,23,24). Actually, international guidelines such as
hose of the European Society of Urogenital Radiology
ecommend the routine use of a hydration protocol before
ontrast exposition (18). Given the fact that an acidic
nvironment promotes free radical formation, hydration
ith bicarbonate theoretically should be more effective, as
roven by Merten et al. (7).
In patients at high risk of developing CIN, the addition
f high-dose N-AC (1,200 mg twice both on the day before
nd the day after the procedure) could play an important
ole in CIN prevention (11,25,26). In this setting, Ochoa et
l. (27) assessed that administration of high doses of N-AC
ith a shortened hydration protocol results in a notably
ower incidence of CIN.
Critical patients, especially those with an ACS undergo-
ng primary PCI or urgent procedures, constitute a group at
igh risk of developing CIN (28,29). This also holds true
or patients with normal renal function, in whom higher
orbidity and mortality rates are found (13). In our study,
Figure 3 Evolution of GFR at Baseline
(Before PCI) and Days 1, 2, 3, and 7
Data are mean  2 SD. GFR  glomerular filtration rate, estimated
using the Levey formula (16); PCI  percutaneous coronary intervention.he incidence of CIN was significantly higher in patients in broup B, allocated to standard hydration after PCI, as
ompared with group A, in which patients received high
oses of N-AC plus an infusion of sodium bicarbonate just
efore contrast injection. This fact was related to a higher,
lthough not significant, incidence of acute renal failure
equiring renal replacement therapy and mortality, and both
ere similar to previously reported data (12,30–32).
Several conditions contribute to renal damage: hemody-
amic instability and hypotension with reduced cardiac
utput, metabolic acidosis secondary to myocardial infarc-
ion (33), the use of large volumes of contrast media, and
ifficulties in establishing a prophylactic therapy in the acute
etting. In patients undergoing emergency PCI, hypoten-
ion and reduced cardiac output, as well certain degree of
ehydration secondary to vomiting and diaphoresis, could
ontribute to prerenal azotemia. We found a relatively high
UN level at baseline in both groups, with levels toward the
pper limit of normal, but with normal SCr levels. This
rerenal azotemia seems to play an important role in the
ctivation of tubuloglomerular feedback and the renin-
ngiotensin system. The rapid bicarbonate infusion, with
he subsequent volume expansion, could stimulate diuresis,
iluting circulating contrast medium and vasoconstriction
ediator concentrations and preventing activation of tubu-
oglomerular feedback (34).
The generation of reactive oxygen species formed as a
esult of postischemic oxidative stress, a pH-dependent
eaction, is known to play a pathogenic role in CIN. In
atients undergoing emergency PCI, this oxidative stress
ould be increased because of metabolic acidosis secondary
o myocardial ischemia (6).
Recently Marenzi et al. (12) have shown a dose-
ependent effect of N-AC for the prevention of CIN in
atients undergoing primary angioplasty. In this study,
atients allocated to receive high doses of N-AC
1,200-mg intravenous bolus of N-AC just before con-
rast medium injection plus 1,200 mg orally twice daily
or the 48 h after PCI) showed a CIN rate of 8% in
ontrast to 33% of the patients in the control group (p 
.001). As CIN criteria, they used a SCr increase of 25%
r more from baseline.
For the same CIN criteria, our study shows a similar
ncidence of CIN in group B, but with an interesting
ncidence of CIN and Clinical Outcomes
Table 3 Incidence of CIN and Clinical Outcomes
Group A Group B p Value
Incidence of CIN (serum
creatinine 0.5 mg/dl)
1 (1.8%) 12 (21.8%) 0.0009*
Acute pulmonary edema 1 (1.8%) 2 (3.6%) 0.62
Anuric acute renal failure 1 (1.8%) 7 (12.7%) 0.032†
Acute renal failure requiring renal
replacement therapy
1 (1.8%) 3 (5.5%) 0.36
Mortality at 7 days 1 (1.8%) 4 (7.3%) 0.21
y Fisher exact test. *95% confidence interval 0.08 to 0.31. †95% confidence interval 0.2 to 0.13.
CIN  contrast-induced nephropathy, absolute increase in serum creatinine 0.5 mg/dl from
aseline.
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Contrast Nephropathy Prevention in Emergency PCI March 27, 2007:1283–8eduction of CIN in group A. We are aware that our
elatively small sample size calls for caution in the interpre-
ation of the results, and that our findings need to be
onfirmed in large multicenter studies.
Our study suggests that a rapid hydration with saline
odium bicarbonate provides a cumulative effect over reac-
ive oxygen species scavenging properties of N-AC, reduc-
ng the formation of these reactive oxygen species.
tudy limitations. The relative limitations of our study are
hose inherent in a single-blind, single-center study with a
mall sample size. Thus, these findings should be confirmed
n a larger multicenter trial.
onclusions. In conclusion, this study shows that a sys-
ematic protocol of a rapid intravenous hydration with
odium bicarbonate plus high doses of N-AC is an effective
nd safe approach in preventing CIN in patients undergoing
rgent PCI.
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